Biologics

From new study findings to product launches, here are eight headlines to know in the orthobiologics space since Jan. 13:

Paul Fleissner, MD, of Fairlawn, Ohio-based Crystal Clinic Orthopaedic Center is the first surgeon to use the RejuvaKnee implant for meniscus repair.

The global spine biologics market is on pace to have a 17.51% compound annual growth rate from 2024 to 2034, according to a Jan. 31 news release from ResearchandMarkets.com.

Stem cell therapies can be effective for treating discogenic low back pain, according to a study published in the January 2025 issue of the International Journal of Spine Surgery.

Jamie Antoine, MD, of Seattle-based Proliance Surgeons performed the first case using CartiHeal's Agili-C implant in Washington state, according to a Jan. 27 LinkedIn post. 

Acuitive Technologies named Wayne Berberian, MD, as its chief medical officer, according to a Jan. 27 news release. 

LifeNet Health and Johnson & Johnson MedTech launched the PliaFX Flo demineralized bone matrix.

SurGenTec earned FDA 510(k) clearance for its OsteoFlo HydroFiber to be used as a stand-alone equivalent to autografts in spine surgeries.

Royal Biologics and Fair Winds Medical partnered to distribute spine and orthopedic biologics, according to a Jan. 16 news release.

From new studies and milestones, here are seven key updates in orthobiologics since Nov. 13.